Marshall Wace’s AEON Biopharma AEON Stock Holding History

Marshall Wace’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,418	Closed	-$13.3M	–	2602
2022 Q4	$13.3M	Hold	18,418	–	–	0.03%	653
2022 Q3	$13.1M	Hold	18,418	–	–	0.03%	688
2022 Q2	$13M	Hold	18,418	–	–	0.03%	695
2022 Q1	$13M	Hold	18,418	–	–	0.02%	697
2021 Q4	$12.9M	Buy	18,418 +9,350	+103%	+$6.57M	0.02%	691
2021 Q3	$6.37M	Buy	9,068 +4,888	+117%	+$3.41M	0.03%	807
2021 Q2	$2.9M	Buy	+4,180	New	+$2.92M	0.01%	1178

Other funds holding AEON

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Marshall Wace's AEON Position: Q1 2023 in Review

Marshall Wace sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 18,418 shares — an estimated $13.3M sold.

Marshall Wace first reported a position in AEON in Q2 2021 and held it in 7 quarters. The position peaked at $13.3M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Marshall Wace reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Marshall Wace sold 18,418 AEON Biopharma shares in Q1 2023, an estimated $13.3M.
Marshall Wace first reported a position in AEON Biopharma in Q2 2021 and held it in 7 quarters.
Marshall Wace's AEON Biopharma position peaked at $13.3M in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.